We are live on ! Find out more
CRMD icon

CorMedix

190 hedge funds and large institutions have $502M invested in CorMedix in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 91 increasing their positions, 28 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 28

55% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 33

19% more capital invested

Capital invested by funds: $421M → $502M (+$80.7M)

10% more funds holding

Funds holding: 172190 (+18)

4.88% more ownership

Funds ownership: 50.37%55.24% (+4.9%)

5% more call options, than puts

Call options by funds: $18.6M | Put options by funds: $17.7M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
190
Holders Change
+18
Holders Change %
+10.47%
% of All Funds
2.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
51
Increased
91
Reduced
28
Closed
33
Calls
$18.6M
Puts
$17.7M
Net Calls
+$879K
Net Calls Change
-$3.75M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$66.2M +$3.97M +328,474 +6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$46.3M -$4.21M -347,887 -8%
Marshall Wace
3
Marshall Wace
United Kingdom
$40.4M +$10.8M +893,518 +35%
DM
4
Deerfield Management
New York
$38.7M +$40.2M +3,323,833 New
State Street
5
State Street
Massachusetts
$21.3M +$2.83M +233,973 +15%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$21.1M +$2.58M +213,450 +13%
Citadel Advisors
7
Citadel Advisors
Florida
$20M +$34.7K +2,872 +0.2%
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$14.7M +$6.2M +512,979 +68%
UBS Group
9
UBS Group
Switzerland
$12.7M +$9.85M +814,964 +295%
Morgan Stanley
10
Morgan Stanley
New York
$9.81M +$923K +76,318 +10%
OAM
11
Oberweis Asset Management
Illinois
$9.14M +$3.64M +300,700 +62%
JF
12
Jump Financial
Illinois
$9M +$9.36M +774,083 New
N
13
Nuveen
North Carolina
$8.09M -$9.35M -772,997 -53%
KCM
14
Kennedy Capital Management
Missouri
$7.66M +$2.16M +178,455 +37%
Raymond James Financial
15
Raymond James Financial
Florida
$7.58M +$6.83M +564,688 +647%
Qube Research & Technologies (QRT)
16
Qube Research & Technologies (QRT)
United Kingdom
$7.41M +$5.11M +422,277 +196%
Northern Trust
17
Northern Trust
Illinois
$7.16M +$585K +48,372 +9%
Charles Schwab
18
Charles Schwab
California
$6.8M +$4.7M +389,027 +199%
PIP
19
Palisades Investment Partners
California
$6.56M +$19.1K +1,579 +0.3%
DTC
20
Deep Track Capital
Connecticut
$5.82M +$6.05M +500,000 New
Invesco
21
Invesco
Georgia
$5.31M +$3.38M +279,963 +158%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$5.22M +$3.13M +258,574 +136%
RA
23
Royce & Associates
New York
$5.13M +$5.34M +441,312 New
OE
24
October Effect
Virginia
$4.89M +$1.35M +111,794 +36%
Millennium Management
25
Millennium Management
New York
$4.6M +$4.1M +339,168 +603%

CRMD Hedge Fund Activity: Q3 2025 in Review

190 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2025, worth a combined $502M — up 19% from $421M a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new CRMD positions and 33 closed out — a net gain of 18 holders — while 91 added to existing stakes and 28 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $40.2M. The largest seller was Nuveen, cutting an estimated $9.35M.

  • 190 institutional investors held CorMedix (CRMD) as of Q3 2025, up from 172 in Q2 2025.
  • Funds reported $502M of CorMedix stock for Q3 2025, up 19% quarter-over-quarter.
  • 51 funds opened new CorMedix positions in Q3 2025 and 33 closed out, a net change of +18 holders.
  • The largest CorMedix buyer in Q3 2025 was Deerfield Management, an estimated $40.2M added.
  • The largest CorMedix seller in Q3 2025 was Nuveen, an estimated $9.35M sold.

Based on aggregated 13F filings for Q3 2025.